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Objectives: To compare comorbidities in a cohort of cyclic citrullinated peptide (CCP) 
antibody positive patients without or prior to onset of inflammatory arthritis (IA) to those 
in patients with early IA.
Methods: Baseline data from two established cohorts were used. The first recruited 
people at risk of IA: CCP antibody positive cases without IA (CCP Cohort, n = 296). The 
second cohort [the Inflammatory Arthritis CONtinuum study (IACON)] recruited patients 
with early IA (n = 725). Proportions of patients with given comorbidities were compared 
between cohorts and then logistic regression was used to determine odds ratios (OR) for 
the CCP cohort having specific comorbidities, compared to IACON patients. Analyses 
adjusted for gender, age, smoking status, and body mass index.
results: Patients from the CCP cohort were younger (mean age 50, compared to 
53 years). The proportion of patients with at least one comorbidity was higher in the 
IACON than the CCP cohort: (40% compared to 24%, respectively). Results of logistic 
regression analyses suggested the odds of hypertension, taking a lipid-lowering agent, 
ischemic heart disease, cerebrovascular disease, lung disease, and diabetes were not 
increased in either cohort. However, patients in the CCP cohort were more likely to be 
taking an antidepressant (OR = 1.62, 95% CI 1.03, 2.56, p = 0.037).
conclusion: There was no significant difference in comorbidities among people with 
CCP antibodies but without IA, compared to those of patients with established IA.
Keywords: comorbidities, inflammatory arthritis, rheumatoid arthritis, cyclic citrullinated peptide antibodies, at-
risk of arthritis, depression and anxiety disorders
inTrODUcTiOn
The presence of comorbidities in inflammatory arthritis (IA) has been linked with worse disease 
outcomes, including lower achievement of disease-remission (1) and premature death in the case 
of rheumatoid arthritis (RA), the commonest subset of IA (2, 3). The prevalence and impact of 
comorbidities on disease outcomes have been primarily studied in RA, with significant comorbidity 
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having been reported at the outset of disease, increasing with 
follow-up (4).
UK data support a changing population demography over time 
with a rising prevalence of risk factors such as obesity (5), but also 
multimorbidity in general (6). Indeed, recent data have shown 
increasing age and level of comorbidity at disease presentation 
in two large RA inception cohorts spanning a 25-year period (7). 
The mechanisms underlying these secular trends are not easy to 
delineate and could be related to several factors, including chang-
ing population demographic trends, changing disease phenotype, 
and treatment use. It is acknowledged that earlier detection and 
screening for comorbidities may explain these trends.
Unlike extra-articular manifestations, which refer to non-
articular features of IA, the term comorbidity in its strict sense is 
used to indicate the presence of an additional disease or condi-
tion, co-existing with the index disease (i.e., IA). Understanding 
the nature and timing/onset of comorbidities in patients with a 
predisposition to or with known IA can help provide insights into 
potential links to the index disease, e.g., common pathophysi-
ological mechanisms and/or iatrogenic effects. This is becoming 
increasingly important in people with a predisposition to IA 
(which may be serological, genetic, or environmental) in order 
to identify and manage the comorbid and index disease with its 
associated pharmacotherapy. Unlike other forms of IA, some 
people at risk of seropositive RA can be identified by the presence 
of cyclic citrullinated peptide (CCP) antibodies, which may be 
detected up to 10 years prior to RA onset (8). Evaluating comor-
bidities in a cohort with a serological predisposition to RA assists 
in determining the onset of comorbidities prior to IA develop-
ment. This formed the rationale for the study, which hypothesized 
that comorbidities start to accumulate in people at risk of IA. The 
study used two separate UK cohorts to investigate the timing and 
nature of comorbidities in people with a predisposition to IA, 
compared to established IA.
MaTerials anD MeThODs
Patient Databases
This study is a comparison of two previously described inception 
cohorts: the CCP cohort study of patients with CCP antibodies, but 
without clinical IA, and the Inflammatory Arthritis CONtinuum, 
IACON, a study of patients with early IA. The CCP cohort study 
has been described previously (9). Briefly, patients in Yorkshire 
aged over 18 who presented to their primary care physician or 
other community service (e.g., physiotherapy) with a new mus-
culoskeletal complaint were invited to participate. Patients were 
also recruited from the Leeds early arthritis clinic, if they did not 
have joint inflammation. Consented patients provided a blood 
sample for anti-CCP2 testing (using the commercially available 
immunocap method, Phadia, Sweden and Germany). Those with 
a positive result were invited to a research clinic based at Chapel 
Allerton Hospital in Leeds. Ethical approval was granted by the 
Leeds ethics committee (06/Q1205/169). Data collection began in 
2007 and is ongoing, including follow-up of cases until the onset 
of IA. The present study used data recorded at the baseline visit 
from all cases included in the CCP cohort who did not have IA 
at the baseline visit. The IACON cohort has also been described 
previously (10). Patients aged over 18 who presented with early IA 
to Leeds Teaching Hospitals NHS Trust between 2010 and 2014 
gave written consent to participate in IACON and attended data 
collection visits for 2 years. Ethical approval was granted by the 
Leeds (West) Research Ethics Committee (09/H1307/98). For 
the present analysis, baseline data from IACON cases with early 
IA and symptom duration of less than 24 months were included, 
except for 34 cases who had also participated in the CCP cohort 
study. We used data collected at the baseline visits of both studies. 
These data included current age and gender, whether the subject 
was a current, ex, or never-smoker, their body mass index (BMI), 
medical problems, and current medications.
comorbidity Data collection
At the initial assessment, people in the CCP cohort were asked 
whether they had specific medical problems, namely hyperten-
sion, ischemic heart disease (IHD), cerebrovascular disease, 
chronic bronchitis or emphysema [recorded as chronic obstruc-
tive pulmonary disease (COPD)], asthma, diabetes (and how it 
was treated), renal or liver disease, inflammatory bowel disease, 
psoriasis, and gout. Participants were also asked whether there 
were any other conditions not mentioned in this list, and these 
were recorded as free text on the clinical record form. Current 
medications were also recorded. Data in this cohort were collected 
by rheumatologists or dedicated research nurses, who questioned 
participants and recorded their responses.
Baseline comorbidity data in IACON were collected by dedi-
cated research nurses or clinicians at baseline. Patients were asked 
about specific diagnoses and their responses noted. In addition 
to the conditions asked about in the CCP clinic, patients were 
also asked whether they had any of the following: hypercholester-
olemia, thyroid disease, depression, anxiety, cancer, peptic ulcer 
disease, epilepsy, demyelination, pseudogout, and osteoarthritis. 
As for the CCP cohort, names and doses of medications were 
also recorded. As there is a well-recognized association of IA with 
IHD, we also sought to identify differences in associations of the 
metabolic syndrome between the two cohorts (hypertension, 
dyslipidemia, diabetes, and IHD).
Data from both cohorts were validated by checking the lists 
of medications, which were recorded at all visits, against the 
comorbidities captured at baseline. Where the diagnosis for 
hypertension was missing but the patient was recorded as taking 
antihypertensive therapy for which no other reason was likely 
(e.g., a patient taking propranolol may have been using it for anxi-
ety), the missing diagnosis was added accordingly. Participants in 
the CCP cohort were not asked about a history of hypercholes-
terolemia; therefore, this diagnosis was recorded only if treated, 
that is, if patients reported taking lipid-lowering therapy. Some 
people from both cohorts reported having both asthma and 
COPD, which likely reflects the nature of the respiratory disease; 
that is, those patients may have elements of both lung problems. 
Therefore, for the purpose of this analysis, asthma/COPD were 
collectively compared, that is, dealt with as a single comorbid-
ity. Patients were not specifically asked about depression and 
anxiety during CCP cohort data collection but these problems 
were sometimes volunteered by the participants or it was noted 
FigUre 1 | Diagram to show how numbers of cases were derived from each cohort.
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that they were taking medication to treat these mental health 
conditions. In order to compare anxiety and depression across 
the two cohorts, we compared numbers of cases using antidepres-
sant medication where antidepressants were prescribed in doses 
typically used to treat depression and not for pain modulation. As 
part of both studies, patients completed the EQ5D questionnaire 
(11), in which they were asked to indicate whether they consid-
ered themselves to be “not anxious or depressed” or “moderately 
anxious or depressed” or “extremely anxious or depressed.” We 
compared the proportions of cases who responded that they were 
moderately or extremely anxious or depressed at the baseline 
visit, across the two cohorts.
statistical analysis
Descriptive statistics were used to compare baseline patient and 
disease characteristics between the two cohorts, using percent-
ages for categorical variables and mean and SD for normally 
distributed variables. Individual comorbidities were compared 
across the two groups. To allow for confounders that may influ-
ence the presence of comorbidities in either group, a series of 
logistic regression models were constructed, with the presence 
of each comorbidity as outcome variables. In order to take into 
consideration some of the heterogeneity of the IACON cohort, which 
included patients with and without CCP antibodies, a sensitivity 
analysis was carried out in which comorbidities were compared 
between the CCP cohort and the 333 IACON cases who were 
CCP positive. Models were adjusted for: sex, age, cohort (that 
is, CCP cohort or IACON), whether the patient was a current 
or ex-smoker compared to those who had never smoked, and 
BMI. To allow for missing data, multiple imputation was used. 
Fifty datasets were imputed, using logistic regression for binary 
variables and predictive mean matching for BMI. The results were 
combined according to Rubin’s rules (12) and then compared to 
analyses of complete cases.
resUlTs
Figure 1 shows how the numbers of cases included in the analy-
sis were derived from those consented to the two cohorts. For 
20 IACON cases and 2 cases from the CCP cohort, details on 
hypertension were amended from “missing” to “present” after the 
data were validated by comparing comorbidities to medications. 
In addition, in five cases from the CCP cohort, the diagnosis of 
hypertension was amended after it was judged to be inaccurate 
according to the drugs data and blood pressure recordings. In 
only five cases from the CCP cohort, the diagnosis of depression 
or anxiety was offered by the patient and recorded as an additional 
comorbidity; however, 33 participants were taking antidepressant 
medication for which no other indication (e.g., pain manage-
ment) was likely from the diagnoses recorded in the database, 
and in these cases the diagnosis of depression was amended from 
“missing” to “present”.
Baseline characteristics of the two cohorts are given in 
Table 1, which also indicates how much of the data were miss-
ing. Participants in the CCP cohort were slightly younger: mean 
age was 49.8  years, compared to 52.8  years in IACON, and 
a greater proportion were female: 73%, compared to 68% in 
IACON. A greater proportion of the CCP cohort were current or 
ex-smokers and the mean BMI of this group was slightly higher 
(28.7, compared to 28.0). Of 271 cases from the CCP cohort, 78 
(29%) progressed to IA, within a median time to progression of 
34 months (IQR 15.5, 63.0). Within IACON, 468 (65%) of the 
cases met ACR/EULAR 2010 or ACR 1987 classification criteria 
for RA either at the baseline visit, or within 2 years of that visit.
Table 1 | Baseline characteristics of the two cohorts.
iacOn (n = 725) ccP cohort (n = 296)
baseline characteristics  
and comorbidities
cases with  
characteristic
cases with missing 
data for variable (%)
cases with  
characteristic
cases with missing 
data for variable (%)
Female (%) 493 (68) 0 (0) 197 (73) 0 (0)
Smoking: never 280 (39) 37 (5) 93 (34) 8 (3)
Current 171 (24) 68 (25)
Ex 237 (33) 102 (38)
Mean age (SD) 52.8 (15.7) 0 (0) 49.8 (13.2) 0
Mean BMI (SD) 28.0 (5.9) 26 (4) 28.7 (6.4) 73 (27)
RF positive (%) 310 (43) 71 (10) 104 (38) 33 (12)
CCP antibody positive (%) 333 (46) 10 (1) 271 (100) 0 (0)
Cases with at least one  
comorbiditya (%)
291 (40) 11 (2) 64 (24) 10 (4)
Hypertension (%) 173 (24) 8 (1) 52 (19) 11 (4)
On lipid-lowering therapy (%) 128 (18) 21 (3) 38 (14) 60 (22)
Ischemic heart disease (IHD) (%) 32 (4) 8 (1) 10 (4) 12 (4)
Cerebrovascular disease (CVD) (%) 18 (3) 9 (1) 6 (2) 13 (4.8)
Peripheral vascular disease (%) 11 (2) 8 (1) 1 (0.4)
COPD/asthma (%) 111 (15) 10 (1) 23 (8) 19 (7)
Diabetes mellitus (%) 48 (7) 5 (1) 12 (4) 15 (6)
Renal disease (%) 15 (2) 8 (1) 7 (2.5) 11 (4)
Chronic liver disease (%) 8 (1) 8 (1) 1 (0.4) 12 (4)
Associations of metabolic  
syndrome (%)b
239 (33) 24 (3) 71 (24) 80 (27)
Taking antidepressants (%) 67 (9) 21 (3) 33 (12) 60 (22)
EQ5D anxious or depressed (%) 173 (24) 8 (1) 52 (19) 11 (4)
BMI, body mass index; CCP, cyclic citrullinated peptide; COPD, chronic obstructive pulmonary disease; RF, rheumatoid factor.
aComorbidities were those specifically asked about in both cohorts: hypertension, IHD, CVD, chronic airways disease or asthma, diabetes mellitus, chronic renal disease, and 
chronic liver disease.
bPatients were considered to have associations of metabolic syndrome if they had hypertension, were taking lipid-lowering therapy, had IHD or diabetes.
Table 2 | Results of logistic regression models of the presence of comorbidities 
in the cyclic citrullinated peptide (CCP) cohort, compared to IACON.
comparison of ccP 
cohort and all iacOn 
cases
comparison of ccP 





Or 95% ci P Or 95% ci P
Hypertension 0.98 0.66 1.43 0.956 1.12 0.72 2.56 0.625
Lipid-lowering 
therapy
1.31 0.86 1.99 0.213 1.02 0.65 1.61 0.932
IHD 1.06 0.49 2.26 0.885 0.56 0.41 2.16 0.891
CVD 1.23 0.46 3.31 0.683 1.33 0.41 4.27 0.634
COPD/Asthma 0.76 0.50 1.17 0.216 0.67 0.42 1.08 0.100




1.12 0.78 1.62 0.539 1.26 0.84 1.88 0.262
Taking 
antidepressants
1.62 1.03 2.56 0.037 1.81 1.03 3.02 0.039
EQ5D anxious or 
depressed
0.57 0.41 0.78 <0.001 0.48 0.34 0.71  < 0.001
CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, 
cardiovascular disease; IHD, ischemic heart disease; OR, odds ratio; P (statistical 
probability).
All models included the following covariates: gender, age, smoking status (ever smoked 
or currently a smoker compared to never smoked) and BMI.
aPatients were considered to have associations of metabolic syndrome if they had 
hypertension, or were taking lipid-lowering therapy, or had IHD or diabetes.
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Table 1 also compares the percentage of patients with each 
comorbidity in the two cohorts. Most comorbidities were 
more prevalent in the IACON group, with a greater propor-
tion of cases from IACON than the CCP cohort having each 
comorbidity, except for taking antidepressants, which was more 
common in the CCP cohort (12%, compared to 9% of patients 
in IACON). Of those taking antidepressants, one-third of those 
from the CCP cohort (11 of 33 people) responded that they were 
moderately or extremely anxious or depressed on the EQ5D 
questionnaire, and a similar proportion of cases from the CCP 
cohort not on antidepressants (29%) responded in the same 
way. A greater proportion of IACON cases taking antidepres-
sants (66%) reported being moderately or extremely anxious or 
depressed, however, a similar proportion of IACON cases not 
on antidepressants (29%) responded in this way to the EQ5D 
questionnaire.
Table  2 gives the results of the logistic regression models. 
The odds of most comorbidities were not increased in either 
CCP or IACON cohorts, with the exception of antidepressants: 
reported antidepressant consumption was more likely in the 
CCP cohort, while reporting of moderate or extreme anxiety or 
depression was more likely in the IACON cohort. Table 2 also 
gives the results of the sensitivity analysis, in which comorbidi-
ties in the CCP cohort were compared to those in CCP antibody 
positive cases from the IACON cohort. This gave similar results 
to the analysis using the whole IACON cohort.
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DiscUssiOn
To our knowledge, there are no previously published data on the 
prevalence of comorbidities in patients with a predisposition to 
RA. Through the CCP cohort, we have used routinely collected 
data from an at-risk population and compared this to a cohort of 
patients with early IA. Such studies are essential to understand-
ing comorbidity burden, timing of comorbidities, and provide 
insights to underlying pathophysiological mechanisms in the 
development of comorbidities. We found that the prevalence of 
comorbidities in IACON were similar to those reported from a 
similar UK cohort of patients with early IA, the Norfolk Arthritis 
Register (13). Data from the Early Arthritis Study have indicated 
that comorbidities in RA increase with time, mainly in car-
diovascular, non-cardiac vascular and respiratory systems, and 
furthermore, specific conditions (e.g., hypertension) occurred 
more frequently than in the general population (4).
The initial comparison of the two cohorts implied that specific 
comorbidities affected greater proportions of patients in IACON 
than the CCP cohort, but further analysis indicated that con-
founders, such as age, gender, smoking, and BMI, might explain 
this difference. Mean BMI was slightly higher in the CCP cohort, 
possibly because overweight and obesity are associated with 
common musculoskeletal conditions, such as osteoarthritis, for 
which patients are likely to see their primary care physician or a 
physiotherapist, and this was one route of recruitment for the CCP 
cohort. We found that the odds of taking an antidepressant was 
significantly greater for patients from the CCP cohort, compared 
to IACON (odds ratio, OR 1.62, 95% CI 1.03, 2.56), suggesting that 
more of these patients were diagnosed with and treated for anxiety 
and depression by their primary care physicians. Furthermore, the 
odds of a patient responding that they were extremely or moderately 
anxious or depressed at their baseline visit were lower in the CCP 
cohort (OR 0.57, 95% CI 0.41, 0.78, p < 0.001). The explanation 
for this paradoxical finding is not clear, but it is noteworthy that 
participants in either study were not asked about a prior history 
of anxiety and depression. IACON cases represented a group of 
patients with confirmed IA, many of whom had been treated with 
corticosteroids. So it is possible that with management of arthritis 
in IACON cases, symptoms of anxiety and depression improved 
and, thus, fewer patients from this cohort were taking antidepres-
sants. Furthermore, corticosteroids may affect mood, with reports 
of both depression and euphoria, and these effects could not be 
taken into account in the present analyses. In comparison, cases 
from the CCP cohort were less likely to report feeling anxious 
or depressed at baseline EQ5D assessment, which is perhaps the 
effect of antidepressant treatment. There are important limita-
tions here: first, the EQ5D data used only represented a single 
occasion for each patient, and furthermore, it is not suitable for 
the diagnosis of depression. Nevertheless, the finding was of 
interest and deserves further exploration. Within other cohorts, 
the psychological implications of an at-risk diagnosis have been 
reported. These have manifest as symptoms associated with anxi-
ety and depression (14–16). Through focus group discussion and 
qualitative research techniques, researchers were able to demon-
strate a theme of fear and uncertainty of a future diagnosis of RA 
(14, 15). Similar findings have been reported in first-degree 
relatives of RA (16). This may help to explain the increased pre-
scription of antidepressants noted in our study.
limitations
This analysis compared data from two distinct cohorts, collected 
at the same center. There were differences in data collection 
between the two cohort studies, which may have biased the 
results. For example, there were different degrees of missingness 
in the two studies with more missing data in the CCP cohort 
than in IACON. To mitigate the impact of missing data, we used 
multiple imputation and 50 datasets to analyze our data. This 
will have helped to reduce bias due to missingness. The differ-
ence in missingness within the two studies is likely due to the 
way the comorbidity data were collected, which was mainly by 
dedicated research nurses in IACON and often by physicians in 
the CCP cohort. Our study was restricted to investigating specific 
comorbidities that participants were asked about and there were 
likely other comorbidities that were not captured. There could 
have been important differences in some comorbidities, such 
as cancer, but these were not included in the list of conditions 
to ask about in the CCP cohort. Some un-captured comorbidi-
ties, such as allergies, could have been indications for the use of 
corticosteroids and could, therefore, have been an additional 
source of unmeasured confounding. Where data were unavail-
able on hypercholesterolemia and depression/anxiety, we used 
pharmacotherapy as an indicator of disease. While this is not 
ideal, because it is possible that people may have these conditions 
without being on a drug treatment for them, this method of using 
pharmacotherapy as a proxy for the presence of a diagnosis is 
widely used (17).
Although the comorbidity data in this study were captured using 
a common questionnaire-style technique, this method is subject 
to recall bias. This is exemplified by the data validation exercise 
whereby we compared diagnoses to the recorded medications and 
found that patients were taking therapy for conditions that they 
had not disclosed. Hopefully, future comorbidity studies will 
make use of linkage to primary care databases, which contain 
contemporary and accurate details of consultations between patients 
and their general practitioners. The cohorts captured data on 
corticosteroid use at baseline and at follow-up assessments, but 
previous use of these medications was not asked about. Although 
this is a potential unmeasured confounder in our analysis, it is 
reasonable to assume that the IACON cohort were more likely 
to have received previous steroid for IA symptoms, and therefore 
the prevalence of diabetes could have been greater in IACON than 
the CCP cohort. As this association was not observed, previous 
use of steroid was unlikely to have had a significant impact on 
the outcome.
In conclusion, the comorbidities present in our CCP cohort 
were similar to those present in IACON, a cohort of patients 
with established IA. This indicates that comorbidities in IA 
may begin to accumulate before the onset of clinically apparent 
inflammation. This finding can be useful information to both 
patients and clinicians for whom the management of arthritis is 
more challenging in the presence of comorbidities. Our study also 
emphasizes the importance of early screening for comorbidities, 
including common mental health diseases such as anxiety and 
6
Twigg et al. Comorbidities in At-Risk CCP Positive Individuals
Frontiers in Medicine | www.frontiersin.org February 2018 | Volume 5 | Article 35
depression in patients presenting to the rheumatology clinic. 
Contemporary management of IA should incorporate a detailed 
assessment of comorbidities on disease presentation: this will 
inform treatment stratification and enable a more holistic 
approach to patient care.
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